<p>Delivery luteolin with folacin-modified nanoparticle for glioma therapy</p>

Abstract

Background: Glioblastoma mutliforme is the most common and has the poorest prognosis of any malignant tumor of the central nervous system. Luteolin, the most abundant xanthone extracted from vegetables and medicinal plants, has been shown to have treatment effects in various cancer cell types. Luteolin is however, hydrophobic and has poor biocompatibility, which leads to low bioavailability. Patients and methods: In this study, folic acid modifiedpoly(ethylene glycol)-poly(ecaprolactone) (Fa-PEG-PCL) nano-micelles was used to encapsulate the luteolin, creating luteolin loaded PEG-PCL (Lut/Fa-PEG-PCL) micelles to treat glioma both in vitro and in vivo. Results: When compared with the free luteolin and Lut/MPEG-PCL, Lut/Fa-PEG-PCL induced a significant cell growth inhibition and more apoptosis of GL261 cells both in vitro and in vivo. The safety assessment also showed no obvious side effects were observed in mice which were administrated with free luteolin or Lut/MPEG-PCL and Lut/Fa-PEG-PCL. Conclusion: These results suggested Lut/Fa-PEG-PCL may be used as an excellent intravenously injectable formulation for the treatment and chemoprevention.

Citrus Flavones: An Update on Sources, Biological Functions, and Health Promoting Properties

“…A strategy for increase the bioavalibility of luteolin was to encapsulate the flavone in folic acid-modified poly(ethyleneglycol)-poly(caprolactone) (Fa-PEG-PCL) nano-micelles that make luteolin much more efficient with respect to when it is in its free form, reducing the concentration needed to kill cells, such as in glioblastoma. The same effect was also reported when xenograft mice were used [130].…”

Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations

“…Of the 24 articles identified in the Cochrane Library, no articles were included, as 16 articles were reviews, 5 were protocols, and 3 were clinical articles in the screening analysis. In total, only 27 full-text articles not duplicated were included in this systematic review [ 32 , 34 , 38 , 41 , 43 , 44 , 45 , 48 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 ], as illustrated in Figure 1 .…”

“…The major tumoral cell characteristics used in the selected studies in our review are shown in Table 1 . Of 27 selected studies for this review, 19 studies (70%) [ 32 , 34 , 38 , 43 , 45 , 48 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 62 , 63 , 64 , 65 , 66 , 67 ] used tumor cells from a human source, 6 (22%) [ 41 , 51 , 54 , 60 , 61 , 68 ] used tumor cell from rats, and 3 studies (11%) [ 44 , 50 , 66 ] used cells from mice. The study by Agemy [ 66 ] used human and mice tumor cell sources and also used lentivirus H-RasV12-shp53 to induce glioma cells.…”

“…Regarding cell lineage of tumor cells from a human source, most studies (79%) [ 32 , 34 , 38 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 62 , 63 , 64 , 66 , 67 ] used the U87-MG cell lineage. For tumor cells from a rat source the C6 lineage was used in almost all studies (83%) [ 41 , 51 , 54 , 60 , 61 ], with the exception of Hekmatara [ 68 ], who used 101/8 cells produced initially by the injection of α-dimethylbenzanthracene into the brain Wistar rats; the GL261 lineage was used in two [ 44 , 50 ] of three studies where the tumor cells were from a mice source.…”

“…The induction characteristics of the glioma model using the cells described above, as well as the animals, are described in Table 2 . In all studies in this review, the tumor model was induced in rodents; mice were used in 21 studies (78%) [ 32 , 34 , 41 , 43 , 44 , 45 , 48 , 50 , 51 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 , 67 ] and rats were used in 6 studies (22%) [ 38 , 54 , 60 , 61 , 65 , 68 ].…”